Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
27,995,500
-
Total 13F shares
-
46,018,197
-
Share change
-
+1,321,524
-
Total reported value
-
$405,811,308
-
Price per share
-
$8.84
-
Number of holders
-
90
-
Value change
-
+$11,501,142
-
Number of buys
-
38
-
Number of sells
-
45
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q3 2020
As of 30 Sep 2020,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) was held by
90 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
46,018,197 shares.
The largest 10 holders included
ARK Investment Management LLC, FMR LLC, Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., BlackRock Inc., Flagship Pioneering Inc., VANGUARD GROUP INC, STATE STREET CORP, Samsara BioCapital, LLC, and JPMORGAN CHASE & CO.
This page lists
90
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.